Skip to content
DraconiticResearch
Search Sources API
182,549 studies31 sourcesUpdated 54 min ago
PreprintCC BY-NDbioRxiv

Hypoxia reduces induced LRIG1 protein despite sustained mRNA induction in colorectal cancer organoids

  1. 1Department of Molecular Biochemistry and Clinical Investigation, Division of Health Sciences, The University of Osaka, Graduate School of Medicine

Abstract

LRIG1 is a negative regulator of receptor tyrosine kinase (RTK) signaling that promotes tumor suppression by driving degradation of EGFR and other RTKs. Inducing LRIG1 expression has therefore been proposed as a strategy to limit cancer cell survival under hypoxia. However, whether hypoxia itself affects LRIG1 expression remains unclear. Here, we investigated how hypoxia affects LRIG1 expression and protein abundance in human cancer datasets and colorectal cancer organoids. Analysis of The Cancer Genome Atlas data across gastrointestinal and other cancers revealed an inverse association between LRIG1 mRNA expression and a hypoxia gene signature that persisted after adjustment for global gene expression. We previously showed that BMPR inhibition induces LRIG1 and suppresses colorectal cancer organoid growth through LRIG1. Under hypoxia, this growth inhibition in colorectal cancer organoids was attenuated, and LRIG1 protein accumulation was reduced despite sustained mRNA induction. Pre-induced LRIG1 protein declined within 3 h of hypoxic exposure in organoids, and ectopically expressed LRIG1 similarly decreased in HEK293 cells. Pharmacological HIF1 inhibition did not prevent LRIG1 protein loss under hypoxia, whereas HIF1 stabilization did not reproduce it under normoxia, suggesting limited HIF1 involvement. Bafilomycin A1 restored LRIG1 protein levels, whereas chloroquine and the proteasome inhibitor MG132 did not, implicating a bafilomycin A1-sensitive lysosomal process. Notably, the hypoxia-induced decrease in LRIG1 was not accompanied by a decrease in total EGFR. These findings suggest that hypoxia limits LRIG1 protein induction, potentially constraining strategies that rely on LRIG1 induction in cancer treatment.

Related

  1. Sustained hypoxia induces divergent response patterns in cardiac metabolic-immune adaptation and circadian rhythm regulation
    Shuting Cheng, Xin Zhuo, Yuhan Deng +4
    PLOS OnePeer-reviewedCC BY 4.0Full textEnzymology & metabolismCell biologyPLOS
  2. Inflammation-Masked Sporadic Colorectal Cancer Detected After Remission Induction in Elderly-Onset Ulcerative Colitis
    Tomotaka Tanaka, Yoshikazu Yoshifuku, Hajime Teshima +7
    ACG case reports journalPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Sustained induction of PMOS-like phenotype in mice exposed to letrozole in drinking water.
    Kennedy A Stevenson, Romy Kerbus, Greg M Anderson +1
    Journal of neuroendocrinologyPeer-reviewedCC BY-NCFull textObstetrics, gynaecology & paediatricsEurope PMC
  4. Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG-2015 French Innovative Leukemia Organization phase 2 randomized trial.
    Arnaud Pigneux, Pierre-Yves Dumas, Marc Bernard +22
    CancerPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  5. Impacts of mutation accumulation and order on tumor initiation revealed by engineered murine colorectal cancer organoids
    Yanping Li, Xiaoxin Xie, Daqi Deng +6
    eLifePeer-reviewedCC BY 4.0Full textOncologyeLifeEurope PMC
BibTeX
@misc{minamiura2026hypoxia,
  title = {{Hypoxia reduces induced LRIG1 protein despite sustained mRNA induction in colorectal cancer organoids}},
  author = {A. Minamiura and S. Aoki and R. Matsuwaka and A. Yoshimoto and Y. Nobori and T. Matsuura and S. Takamatsu and E. Miyoshi and J. Kondo},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.19.760078},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.19.760078v1},
  note = {CC BY-ND},
}
RIS
TY  - UNPB
TI  - Hypoxia reduces induced LRIG1 protein despite sustained mRNA induction in colorectal cancer organoids
AU  - A. Minamiura
AU  - S. Aoki
AU  - R. Matsuwaka
AU  - A. Yoshimoto
AU  - Y. Nobori
AU  - T. Matsuura
AU  - S. Takamatsu
AU  - E. Miyoshi
AU  - J. Kondo
PY  - 2026
DA  - 2026/10/19
PB  - bioRxiv
DO  - 10.64898/2026.10.19.760078
UR  - https://www.biorxiv.org/content/10.64898/2026.10.19.760078v1
AB  - LRIG1 is a negative regulator of receptor tyrosine kinase (RTK) signaling that promotes tumor suppression by driving degradation of EGFR and other RTKs. Inducing LRIG1 expression has therefore been proposed as a strategy to limit cancer cell survival under hypoxia. However, whether hypoxia itself affects LRIG1 expression remains unclear. Here, we investigated how hypoxia affects LRIG1 expression and protein abundance in human cancer datasets and colorectal cancer organoids. Analysis of The Cancer Genome Atlas data across gastrointestinal and other cancers revealed an inverse association between LRIG1 mRNA expression and a hypoxia gene signature that persisted after adjustment for global gene expression. We previously showed that BMPR inhibition induces LRIG1 and suppresses colorectal cancer organoid growth through LRIG1. Under hypoxia, this growth inhibition in colorectal cancer organoids was attenuated, and LRIG1 protein accumulation was reduced despite sustained mRNA induction. Pre-induced LRIG1 protein declined within 3 h of hypoxic exposure in organoids, and ectopically expressed LRIG1 similarly decreased in HEK293 cells. Pharmacological HIF1 inhibition did not prevent LRIG1 protein loss under hypoxia, whereas HIF1 stabilization did not reproduce it under normoxia, suggesting limited HIF1 involvement. Bafilomycin A1 restored LRIG1 protein levels, whereas chloroquine and the proteasome inhibitor MG132 did not, implicating a bafilomycin A1-sensitive lysosomal process. Notably, the hypoxia-induced decrease in LRIG1 was not accompanied by a decrease in total EGFR. These findings suggest that hypoxia limits LRIG1 protein induction, potentially constraining strategies that rely on LRIG1 induction in cancer treatment.
ER  -